The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Open accessAbstract
BACKGROUND: The European Atherosclerosis Society–European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management. CONTENT: We critically examined LDL cholesterol, non-HDL cholesterol, apolipoprotein B (apoB), and LDL particle number assays based on key criteria for medical application of biomarkers. (a) Analytical performance: Discordant LDL cholesterol quantification occurs when LDL cholesterol is measured or calculated with different assays, especially in patients with hypertriglyceridemia >175 mg/dL (2 mmol/L) and low LDL cholesterol concentrations <70 mg/dL (1.8 mmol/L). Increased lipoprotein(a) should be excluded in patients not achieving LDL cholesterol goals with treatment. Non-HDL cholesterol includes the atherogenic risk component of remnant cholesterol and can be calculated in a standard nonfasting lipid panel without additional expense. ApoB more accurately reflects LDL particle number. (b) Clinical performance: LDL cholesterol, non-HDL cholesterol, and apoB are comparable predictors of cardiovascular events in prospective population studies and clinical trials; however, discordance analysis of the markers improves risk prediction by adding remnant cholesterol (included in non-HDL cholesterol) and LDL particle number (with apoB) risk components to LDL cholesterol testing. (c) Clinical and cost-effectiveness: There is no consistent evidence yet that non-HDL cholesterol-, apoB-, or LDL particle-targeted treatment reduces the number of cardiovascular events and healthcare-related costs than treatment targeted to LDL cholesterol. SUMMARY: Follow-up of pre- and on-treatment (measured or calculated) LDL cholesterol concentration in a patient should ideally be performed with the same documented test method. Non-HDL cholesterol (or apoB) should be the secondary treatment target in patients with mild to moderate hypertriglyceridemia, in whom LDL cholesterol measurement or calculation is less accurate and often less predictive of cardiovascular risk. Laboratories should report non-HDL cholesterol in all standard lipid panels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Calculated by subtracting HDLC from TC, non-HDLC represents the cholesterol in all particles causing cardiovascular disease, that is, LDL, VLDL, IDL, and Lp(a); in the nonfasting state this additionally includes the cholesterol in chylomicrons and their remnant particles [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It should be noted that most clinical trials demonstrating the evidence base for clinical benefit of LDLC lowering have used Friedewald cLDLC; thus it cannot be excluded that dLDLC rather than cLDLC is the method that misclassifies risk [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although apoB demonstrates competitive clinical performance compared with non-HDLC, there is no evidence yet of significant population healtheconomic benefit of intensifying pharmacological intervention aiming to further reduce apoB at very low concentrations of LDLC [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may compensate for the under-or overestimation of LDLC in terms of clinical decision making, given the uncertainty of dLDLC measurements or the Friedewald calculation in dyslipidemic samples when LDLC lowering approaches 1.4 mmol/L, and non-HDLC can be used at high TG ≥ 4.5 mmol/l.”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the present purposes, the combination of non-HDLC with Martin-Hopkins cLDLC may be considered as an appropriate strategy to guide therapy and they can be calculated from the standard lipid profile [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Taken together with the evidence that apoB can be measured more accurately, more precisely, and more selectively than LDL-C or non-HDL-C,1,29–31”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RemnantC, measured or calculated, differs from non-HDLC in that non-HDLC contains RemnantC plus LDLC and does not differentiate between these two causal risk factors [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Direct LDLC measurement should preferably be used in the calculation of RemnantC; otherwise RemnantC simply equals TG/2.2 (in mmol/L) when Friedewald-calculated LDLC is used, i.e.TC -HDLC -(TC -HDLC -TG/2.2),and it does not add clinical information beyond TG concentration [1]”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Not uncommonly, changes in a patient's LDLC test result over time are within the range of uncertainty of laboratory method variation and may not be due to therapeutic intervention [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Guideline-recommended therapeutic goals for non-HDLC are arbitrarily set typically at 0.8 mmol/L (30 mg/dL) higher than LDLC goals (Table 6); this value is based on the assumption that the”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, even when cross-reactivity of immunoassays to apoB48 occurs in nonfasting measurements, apoB quantification is essentially an estimate of LDL particle number if TG and Lp(a) concentrations are low [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Guideline-based non-HDLC thresholds have been arbitrarily defined by consensus of expert groups, based on the assumption that a normal VLDLC concentration exists when TG are < 1.7 mmol/L, which is < 0.8 mmol/L as estimated by the Friedewald formula [1,2].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Given the uncertainty of measurements and calculations of LDLC across different methods and laboratories, in hypertriglyceridemic patients the decision thresholds may not always be assumed to be universally applicable [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, the compromised accuracy of dHDLC assays in samples with hypertriglyceridemia reduces the benefit in reporting non-HDLC in some individuals in whom an apoB or LDLP measurement may be clinically useful [1].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [1]
In the citing paper
“Non-fasting TG is equivalent, if not superior, to fasting TG in assessing potential ASCVD risk.78,79”
In the citing paper
“However, this study [77] and another based on the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial [78] have shown that large absolute changes in Lp(a) may be needed to produce a clinically meaningful reduction in the risk of ASCVD events.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Self-citationSilverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationAnderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citationJellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Self-citationMartin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw152 · Cited by 847
Self-citationBoekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Self-citationTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationLangsted, A., Freiberg, J. J., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.108.804146 · Cited by 588
Self-citationVery Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Self-citationNordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Self-citationGotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 558
Lipid-Related Markers and Cardiovascular Disease Prediction
The Emerging Risk Factors Collaboration (2012) · JAMA · doi:10.1001/jama.2012.6571 · Cited by 547
Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
Self-citationPischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Self-citationRobinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.4030 · Cited by 496
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Self-citationLipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Barter, P. J., Ballantyne, C. M., Carmena, R., Cabezas, M. C., Chapman, M. J., Couture, P., Graaf, J. D., Durrington, P. N., Færgeman, O., Frohlich, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 465
Self-citationKhera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461
Self-citationMora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Circulation · doi:10.1161/circulationaha.108.777334 · Cited by 445
Self-citationNauck, M., Warnick, G. R., & Rifai, N. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.236 · Cited by 442
Self-citationCromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 429
Martin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428
Bachorik, P. S., & Ross, J. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1414 · Cited by 412
Anti-PCSK9 Monotherapy for Hypercholesterolemia
Koren, M. J., Lundqvist, P., Bolognese, M., Neutel, J. M., Monsalvo, M. L., Yang, J., Kim, J. B., Scott, R., Wasserman, S. M., & Bays, H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.018 · Cited by 411
Miller, W. G., Myers, G. L., Sakurabayashi, I., Bachmann, L. M., Caudill, S. P., Dziekonski, A., Edwards, S., Kimberly, M. M., Korzun, W. J., Leary, E. T., et al. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.142810 · Cited by 386
Self-citationClinical implications of discordance between low-density lipoprotein cholesterol and particle number
Otvos, J. D., Mora, S., SHALAUROVA, I. Y., Greenland, P., Mackey, R. H., & Goff, D. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.001 · Cited by 385
Self-citationMora, S., Szklo, M., Otvos, J. D., Greenland, P., Psaty, B. M., Goff, D. C., O’Leary, D. H., Saad, M. F., Tsai, M. Y., & Sharrett, A. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.007 · Cited by 380
Self-citationRobinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326
Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O. S., Djuric, D. M., Владиславович, Е. М., Fras, Z., Katsiki, N., Langlois, M. R., Latkovskis, G., et al. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux047 · Cited by 303
Self-citationLDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274 · cited 1×
“with PCSK9 inhibitors), are now available (11, 12).”
BackgroundDavidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Self-citationLipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv563 · Cited by 256
Mora, S., Buring, J. E., & Ridker, P. M. (2014) · Circulation · doi:10.1161/circulationaha.113.005873 · Cited by 255
Self-citationMarcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.586 · Cited by 243
El Harchaoui, K., van der Steeg, W. A., Stroes, E. S. G., Kuivenhoven, J. A., Otvos, J. D., Wareham, N. J., Hutten, B. A., Kastelein, J. J. P., Khaw, K.-T., & Boekholdt, S. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.043 · Cited by 239
A Test in Context: Lipid Profile, Fasting Versus Nonfasting
Nordestgaard, B. G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.006 · Cited by 223
Self-citationRidker, P. M., Mora, S., & Rose, L. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw046 · Cited by 222
Self-citationJepsen, A.-M. K., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253757 · Cited by 218
Self-citationNordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G. D., Baum, H. H. E., Bruckert, É., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.258897 · Cited by 205
Self-citationFrom biomarkers to medical tests: the changing landscape of test evaluation
Horvath, A. R., Lord, S. J., StJohn, A., Sandberg, S., Cobbaert, C. M., Lorenz, S., Monaghan, P. J., Verhagen-Kamerbeek, W. D. J., Ebert, C., & Bossuyt, P. M. M. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.09.018 · Cited by 203
Self-citationLiposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy
Mallol, R., Amigó, N., Rodriguez, M. A., Heras, M., Vinaixa, M., Plana, N., Rock, E., Ribalta, J., Yanes, Ó., Masana, L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.d050120 · Cited by 199
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.037 · Cited by 197
Myers, G. L., Christenson, R. H., Cushman, M., Ballantyne, C. M., Cooper, G. R., Pfeiffer, C. M., Grundy, S. M., Labarthe, D. R., Levy, D. A., Rifai, N., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.115899 · Cited by 186
Self-citationWilkins, J. T., Li, R. C., Sniderman, A., Chan, C., & Lloyd-Jones, D. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.055 · Cited by 181
Joshi, P. H., Khokhar, A. A., Massaro, J. M., Lirette, S. T., Griswold, M. E., Martin, S. S., Blaha, M. J., Kulkarni, K. R., Correa, A., D'Agostino, R. B., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002765 · Cited by 177
Mora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.117929 · Cited by 176
Self-citationResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 174
Evaluating the Clinical Utility of a Biomarker
Pletcher, M. J., & Pignone, M. P. (2011) · Circulation · doi:10.1161/circulationaha.110.943860 · Cited by 172
Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study
Thomsen, M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.219881 · Cited by 171
Self-citationPechlaner, R., Tsimikas, S., Yin, X., Willeit, P., Baig, F., Santer, P., Oberhollenzer, F., Egger, G., Witztum, J. L., Alexander, V. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.065 · Cited by 171
NMR measurement of LDL particle number using the Vantera® Clinical Analyzer
Matyus, S. P., Braun, P. J., Wolak, J. E., Jeyarajah, E. J., SHALAUROVA, I. Y., Xu, Y., Warner, S. M., Clement, T. S., Connelly, M. A., & Fischer, T. J. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.07.015 · Cited by 169
Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.
Ip, S., Lichtenstein, A. H., Chung, M., Lau, J., & Balk, E. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-7-200904070-00007 · Cited by 163
Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157
Benn, M., Nordestgaard, B. G., Jensen, G. B., & Tybjærg‐Hansen, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255580.73689.8e · Cited by 152
Self-citationYeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Thanassoulis, G., Williams, K., Ye, K., Brook, R., Couture, P., Lawler, P. R., de Graaf, J., Furberg, C. D., & Sniderman, A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000759 · Cited by 148
Lawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005549 · Cited by 145 · cited 1×
“Residual risk is also associated with ontreatment non-HDLC and more prominently with concentrations of smaller VLDLP, which may represent remnants of TG-rich lipoproteins that are insufficiently reduced by LDL-targeted statin dosages (85, 119, 122).”
BackgroundSelf-citationSattar, N. A., Williams, K., Sniderman, A. D., D’Agostino, R., & Haffner, S. M. (2004) · Circulation · doi:10.1161/01.cir.0000145660.60487.94 · Cited by 139
Sniderman, A. D., Islam, S., Yusuf, S., & McQueen, M. J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.039 · Cited by 138
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Beyond Low-Density Lipoprotein Cholesterol
Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136
Varbo, A., & Nordestgaard, B. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000429 · Cited by 135
Self-citationVarbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.279463 · Cited by 133
Self-citationWilliams, K., Sniderman, A. D., Sattar, N. A., D’Agostino, R., Wagenknecht, L. E., & Haffner, S. M. (2003) · Circulation · doi:10.1161/01.cir.0000097113.11419.9e · Cited by 131
Mora, S., Caulfield, M. P., Wohlgemuth, J., Chen, Z., Superko, H. R., Rowland, C. M., Glynn, R. J., Ridker, P. M., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016857 · Cited by 126
Self-citationContois, J. H., Warnick, G. R., & Sniderman, A. D. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.05.004 · Cited by 123
Cole, T. G., Contois, J. H., Csako, G., McConnell, J. P., Remaley, A. T., Devaraj, S., Hoefner, D. M., Mallory, T., Sethi, A. A., & Warnick, G. R. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196733 · Cited by 122
Self-citationFasting versus nonfasting and low-density lipoprotein cholesterol accuracy
Sathiyakumar, V., Park, J., Golozar, A., Lazo, M., Quispe, R., Guallar, E., Blumenthal, R. S., Jones, S. R., & Martin, S. S. (2018) · Circulation · doi:10.1161/circulationaha.117.030677 · Cited by 122
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Sniderman, A. D., Couture, P., & Graaf, J. D. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.50 · Cited by 118
Sniderman, A. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.006 · Cited by 116
van Deventer, H. E., Miller, W. G., Myers, G. L., Sakurabayashi, I., Bachmann, L. M., Caudill, S. P., Dziekonski, A., Edwards, S., Kimberly, M. M., Korzun, W. J., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.154773 · Cited by 112
Self-citationMora, S., Glynn, R. J., Boekholdt, S. M., Nordestgaard, B. G., Kastelein, J. J. P., & Ridker, P. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.035 · Cited by 108
Self-citationvan den Broek, I., Romijn, F. P. H. T. M., Nouta, J., van der Laarse, A., Drijfhout, J. W., Smit, N. P. M., van der Burgt, Y. E. M., & Cobbaert, C. M. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.246702 · Cited by 105
Self-citationLawler, P. R., Akinkuolie, A. O., Ridker, P. M., Sniderman, A. D., Buring, J. E., Glynn, R. J., Chasman, D. I., & Mora, S. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.264515 · Cited by 104
Self-citationBallantyne, C. M., Raichlen, J. S., & Cain, V. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.052 · Cited by 102
Marcovina, S. M., Gaur, V. P., & Albers, J. J. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.574 · Cited by 102
Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.111401 · Cited by 94
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use
Mora, S. (2009) · Circulation · doi:10.1161/circulationaha.108.819359 · Cited by 89
Self-citationLi, K. M., Wilcken, D. E. L., & Dudman, N. P. B. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.571 · Cited by 88
Miida, T., Nishimura, K., Okamura, T., Hirayama, S., Ohmura, H., Yoshida, H., Miyashita, Y., Ai, M., Tanaka, A., Sumino, H., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.022 · Cited by 74
Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state
White, K. T., Moorthy, M. V., Akinkuolie, A. O., Demler, O., Ridker, P. M., Cook, N. R., & Mora, S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241752 · Cited by 74
Self-citationValidation of a proposed novel equation for estimating LDL cholesterol
Meeusen, J. W., Lueke, A. J., Jaffe, A. S., & Saenger, A. K. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.227710 · Cited by 72
Langlois, M. R., Descamps, O. S., van der Laarse, A., Weykamp, C., Baum, H., Pulkki, K., von Eckardstein, A., De Bacquer, D., Borén, J., Wiklund, O., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.016 · Cited by 72
Self-citationStandardization of Measurements for Cholesterol, Triglycerides, and Major Lipoproteins
Warnick, G. R., Kimberly, M. M., Waymack, P. P., Leary, E. T., & Myers, G. L. (2008) · Laboratory Medicine · doi:10.1309/6ul9rhjh1jffu4py · Cited by 72
Lawler, P. R., Akinkuolie, A. O., Harada, P. H. N., Glynn, R. J., Chasman, D. I., Ridker, P. M., & Mora, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007402 · Cited by 69
Self-citationElshazly, M. B., Martin, S. S., Blaha, M. J., Joshi, P. H., Toth, P. P., McEvoy, J. W., Al-Hijji, M. A., Kulkarni, K. R., Kwiterovich, P. O., Blumenthal, R. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.045 · Cited by 68
Comparability of methods for LDL subfraction determination: A systematic review
Chung, M., Lichtenstein, A. H., Ip, S., Lau, J., & Balk, E. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.011 · Cited by 65
Oliveira, M. J. A., van Deventer, H. E., Bachmann, L. M., Warnick, G. R., Nakajima, K., Nakamura, M., Sakurabayashi, I., Kimberly, M. M., Shamburek, R. D., Korzun, W. J., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.04.009 · Cited by 64
Self-citationKronenberg, F., Lingenhel, A., Lhotta, K., Rantner, B., Kronenberg, M. F., König, P., Thiery, J., Koch, M., von Eckardstein, A., & Dieplinger, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00737.x · Cited by 62
Self-citationBiomarker development targeting unmet clinical needs
Monaghan, P. J., Lord, S. J., John, A. S., Sandberg, S., Cobbaert, C. M., Lennartz, L., Verhagen-Kamerbeek, W. D. J., Ebert, C., Bossuyt, P. M., & Horvath, A. R. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.037 · Cited by 61
Self-citationSandhu, P. K., Musaad, S. M. A., Remaley, A. T., Buehler, S. S., Strider, S., Derzon, J. H., Vesper, H. W., Ranne, A., Shaw, C. S., & Christenson, R. H. (2016) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.021006 · Cited by 55
Self-citationComparison of equations for the calculation of LDL-cholesterol in hospitalized patients
Martins, J., Olorunju, S. A. S., Murray, L., & Pillay, T. S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.037 · Cited by 51
Accuracy of low-density lipoprotein cholesterol estimation at very low levels
Quispe, R., Hendrani, A. D., Elshazly, M. B., Michos, E. D., McEvoy, J. W., Blaha, M. J., Banach, M., Kulkarni, K. R., Toth, P. P., Coresh, J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0852-2 · Cited by 50
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Miremadi, S., Sniderman, A. D., & Frohlich, J. J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.3.484 · Cited by 48
Cobbaert, C. M., Weykamp, C. W., Baadenhuijsen, H., Kuypers, A. W. H. M., Lindemans, J. W., & Jansen, R. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1526 · Cited by 45
Self-citationSystematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
Rosenson, R. S., & Underberg, J. A. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6477-6 · Cited by 45
ApoB versus non-HDL-C: What to do when they disagree
Sniderman, A. D., Williams, K., & Cobbaert, C. M. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0054-2 · Cited by 45
Self-citationdeGoma, E. M., Davis, M. D., Dunbar, R. L., Mohler, E. R., Greenland, P., & French, B. C. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.012 · Cited by 43
Jarauta, E., Mateo‐Gállego, R., Gilabert, R., Plana, N., Junyent, M., de Groot, E., Cenarro, A., Masana, L., Ros, E., & Civeira, F. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.10.011 · Cited by 40
Self-citationWong, N. D., Chuang, J., Zhao, Y., & Rosenblit, P. D. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.003 · Cited by 39
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6666-1 · Cited by 36
Steffen, B. T., Guan, W., Remaley, A. T., Paramsothy, P., Heckbert, S. R., McClelland, R. L., Greenland, P., Michos, E. D., & Tsai, M. Y. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304349 · Cited by 35
Self-citationGrundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.003 · Cited by 33
Smit, N. P. M., Romijn, F. P. H. T. M., van den Broek, I., Drijfhout, J. W., Haex, M., van der Laarse, A., van der Burgt, Y. E. M., & Cobbaert, C. M. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.06.015 · Cited by 32
Self-citationOtokozawa, S., Ai, M., Asztalos, B. F., White, C. C., Demissie, S., Cupples, L. A., Nakajima, K., Wilson, P. W. F., & Schaefer, E. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.041 · Cited by 32
Clouet-Foraison, N., Gaie-Levrel, F., Gillery, P., & Delatour, V. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0091 · Cited by 30 · cited 1×
“Therefore, standardization of NMR spectral analysis is urgently needed, as well as harmonization to a unique reference material to allow comparability of NMR data with other subfractionation techniques (72).”
MethodVesper, H. W., Wilson, P. W. F., & Rifai, N. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.178202 · Cited by 27
Self-citationEnkhmaa, B., Anuurad, E., Zhang, W., & Berglund, L. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.04.035 · Cited by 25
Lund, S. S., Petersen, M., Frandsen, M., Smidt, U., Parving, H., Vaag, A. A., & Jensen, T. J. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.133868 · Cited by 22
Querton, L., Buysschaert, M., & Hermans, M. P. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.002 · Cited by 22
A comparative study of four independent methods to measure LDL particle concentration
Hopkins, P. N., Pottala, J. V., & Nanjee, M. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.042 · Cited by 20
Soran, H., France, M. W., Kwok, S., Dissanayake, S., Charlton-Menys, V., Younis, N. N., & Durrington, P. N. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.010277 · Cited by 20
Masana, L., Ibarretxe, D., Heras, M., Cabré, A., Ferré, R., Merino, J., Plana, N., & Girona, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.001 · Cited by 19
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study
Folse, H. J., Goswami, D., Rengarajan, B., Budoff, M. J., & Kahn, R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.027 · Cited by 19
Saeedi, R., Li, M., Allard, M., & Frohlich, J. J. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.04.023 · Cited by 18
Langlois, M. R. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0636 · Cited by 15
Self-citationRizzo, J. A., Mallow, P. J., Waters, H. C., & Pokrywka, G. S. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.06.004 · Cited by 13
Grabner, M., Winegar, D. A., Punekar, R. S., Quimbo, R. A., Cziraky, M. J., & Cromwell, W. C. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.10.028 · Cited by 10
The Good, the Bad, and the Atherogenic
Reiber, I., Mező, I., Márk, L., & Paragh, G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.058 · Cited by 5
Harchaoui, A. K. E., van der Steeg, W. A., Stroes, E. S. G., Kuivenhoven, J. A., Otvos, J. D., Wareham, N. J., Hutten, B. A., Jp, J., Khaw, K., & Boekholdt, S. M. (2007) · Cited by 4
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationPearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J. J., Grégoire, J. C., Grover, S. A., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.016 · Cited by 900
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review
Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3780 · Cited by 593
Self-citationSampson, M. L., Ling, C., Sun, Q., Harb, R., Ashmaig, M., Warnick, R., Sethi, A. A., Fleming, J. K., Otvos, J. D., Meeusen, J. W., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0013 · Cited by 593
Self-citation
Metadata
- Authors
- Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., Catapano, A., Descamps, O. S., von Eckardstein, A., Kamstrup, P. R., Kolovou, G., Kronenberg, F., Langsted, A., Pulkki, K., Rifai, N., Sypniewska, G., Wiklund, O., Nordestgaard, B. G., & for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative
- Affiliations
- Ghent University (BE)
- Inserm (FR)
- Leiden University Medical Center (NL)
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- Instituto de Salud Carlos III (ES)
- The University of Western Australia (AU)
- Sahlgrenska University Hospital (SE)
- Klinikum Ludwigsburg (DE)
- Pitié-Salpetriere University Hospital, Paris, France
- University of Milan (IT)
- Hôpital de Jolimont (BE)
- Institute for Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
- University of Copenhagen (DK)
- Onassis Cardiac Surgery Center (GR)
- Innsbruck Medical University (AT)
- University of Turku (FI)
- Boston Children's Hospital (US)
- Department of Laboratory Medicine, Collegium Medicum, NC University, Bydgoszcz, Poland
- Corresponding author
- Langlois, Michel R
- ORCID
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-01
- Volume
- 64
- Issue
- 7
- Pages
- 1006-1033
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2800713945
- Cited by
- 260
- References
- 146
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 28 · 2023: 32 · 2022: 27 · 2021: 49 · 2020: 43 · 2019: 32 · 2018: 9
- FWCI
- 34.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- atherogenic lipoproteins, LDL cholesterol, non-HDL cholesterol, apolipoprotein B, LDL particle number, remnant cholesterol, lipoprotein(a), hypertriglyceridemia, cardiovascular risk prediction, treatment goals, cost-effectiveness, personalized medicine
- MeSH terms
- Humans, Cholesterol, LDL, Consensus, Atherosclerosis, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
